Loading data for IMMX — first visit, this takes a few seconds.

Immix Biopharma, Inc. (IMMX)

NasdaqCM: IMMX · 即時價格 · USD

12.11

-0.59 (-4.65%)

收盤價： Sep 11, 2026, 8:00 PM

12.21

+0.58%

盤後: 7:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	9.47
市值	868M
營收 (ttm)	n/a
淨利（ttm）	-39.9M
	0.20
	-0.88
	n/a
	-13.29
P/B (ttm)	3.79
P/S (ttm)	0.00
財報日期	Nov 6, 2026

賣價	12.05
成交量	640,492
20 日平均成交量	1,852,532
開盤價	12.86
前收盤價	12.70
當日區間	12.02 - 13.29
52 週範圍	1.94 - 15.10
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Dec 16, 2021

員工 21

證券交易所 NasdaqCM

股票代號 IMMX

網站 https://www.immixbio.com

完整的公司簡介

財務表現

Immix Biopharma 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -29.44M，較前期增加 36.21%。

財務報表

財報驚奇

Immix Biopharma 已於 Aug 7, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.18 低於預期 0.00, 年增 18.18% 成長.

下次財報發布

Immix Biopharma, Inc. 的下次財報預計於 Nov 6, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

1 月前 · Investor's Business Daily

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

2 月前 · Zacks

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

3 月前 · Simply Wall St.

Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

3 月前 · Zacks

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

4 月前 · Simply Wall St.

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

第 1 頁，共 2 頁

Immix Biopharma, Inc. (IMMX)